Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04835584
Title KRT-232 and TKI Study in Chronic Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Kartos Therapeutics, Inc.
Indications

chronic myeloid leukemia

Therapies

Dasatinib + KRT-232

KRT-232 + Nilotinib

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | CAN

Additional content available in CKB BOOST